Literature DB >> 7032829

The antihypertensive effects of ketanserin (R 41468), a novel 5-hydroxytryptamine-blocking agent, in patients with essential hypertension.

J De Crée, J Leempoels, H Geukens, W De Cock, H Verhaegen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7032829     DOI: 10.1042/cs061473s

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


× No keyword cloud information.
  6 in total

1.  Ketanserin combined with a beta-blocker or diuretic in essential hypertension. A multicentre study.

Authors:  C Bartoloni; P Dupont; H Feltkamp; C I Johnston; K Steinbach; H Zilcher; F Kaindl
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  A new selective antagonist of vascular serotonin receptors lowers blood pressure in spontaneously hypertensive rats.

Authors:  P Salvati; F Vaghi; M Colombo; G Bianchi
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

4.  Ketanserin without effects on basal anterior pituitary hormone secretion in healthy subjects.

Authors:  A Gordin; P Mustajoki; R Pelkonen
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

Review 5.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

6.  Ketanserin in essential hypertension: a double-blind, placebo-controlled study.

Authors:  H A Cameron; L E Ramsay
Journal:  Postgrad Med J       Date:  1985-07       Impact factor: 2.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.